دورية أكاديمية
أعرض في EDS

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.

التفاصيل البيبلوغرافية
العنوان: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
المؤلفون: Disis ML; Cancer Vaccine Institute, University of Washington, Seattle, Washington, USA., Adams SF; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA., Bajpai J; Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Butler MO; Department of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Curiel T; Dartmouth-Hitchcock's Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire, USA., Dodt SA; A Cottage for Counseling, Palm City, Florida, USA., Doherty L; Program in Women's Oncology, Women and Infants Hospital of Rhode Island, Providence, Rhode Island, USA., Emens LA; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Friedman CF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, New York, USA., Gatti-Mays M; Pelotonia Institute for Immuno-Oncology, Division of Medical Oncology, The Ohio State University, Columbus, Ohio, USA., Geller MA; Department of Obstetrics, Gynecology & Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota, USA., Jazaeri A; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., John VS; Department of Medical Oncology & Hematology, Northwell Health Cancer Institute, Lake Success, New York, USA., Kurnit KC; University of Chicago Medicine Comprehensive Cancer Center, University of Chicago, Chicago, Illinois, USA., Liao JB; University of Washington School of Medicine, Seattle, Washington, USA., Mahdi H; Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Mills A; Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA., Zsiros E; Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA., Odunsi K; The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, USA odunsia@bsd.uchicago.edu.
المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jun; Vol. 11 (6).
نوع المنشور: Practice Guideline; Journal Article
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd.
Original Publication: London : BioMed Central, 2013-
مواضيع طبية MeSH: Genital Neoplasms, Female*/therapy , Uterine Cervical Neoplasms*/etiology, Female ; Humans ; Immunotherapy ; Quality of Life ; Treatment Outcome
مستخلص: Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer.
Competing Interests: Competing interests: SFA – Contracted Research: Astra Zeneca. JB – Contracted Research: (institutional financial interests for conducted research) Eli Lilly, Novartis, Roche, Samsung Bioepis co. Ltd, Sun Pharma, Paxman Coolers. MOB – Consulting Fees: Bristol-Myers Squibb, EMD Serono, GSK, Immunocore, Immunovaccine, Merck & Co., Novartis, Sanofi-Genzyme, Turnstone Biologics, Sun Pharma; Contracted Research: Merck, Takara Bio. TJC – Consulting Fees: Agenus, Xencor; Ownership Interest less than 5%: Agenus, Xencor. MLD – Fees for non-CE services: PER; Contracted Research: Pfizer, EMD Serono, Bavarian Nordisk, Precigen, Epithany, Veanna; Other: Editor-in-Chief, JAMA Oncology; Other Details: Compensation by JAMA. LD – Consulting: Pfizer. LAE – Consulting Fees: Genentech, F Hoffman La Roche, Chugai, GPCR, Gilead, Immune Onc, Immutep, Shionogi, Mersana; Consulting (no fees): Immutep; Contracted Research: Abbvie, Astrazeneca, Bolt Therapeutics, Bristol Myers Squibb, Compugen, Corvus, CytomX, EMD Serono, Genentech, F Hoffman La Roche, Immune Onc, Maxcyte, Merck, Next Cure, Silverback, Takeda, Tempest; Other: HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco, Cornell University, Dana Farber Cancer Institute, Stand Up to Cancer (these are grants from non-industry entities). CFF – Consulting Fees: Bristol-Myers Squibb, Arch Oncology, Seagen, Aptitude Health, OncLive, Aadi Biosciences/GOG Partners; Contracted Research: Genentech/Roche, Astra Zeneca, Bristol Meyers Squibb, Merck, Daiichi; Other: Merck, Genentech; Other Details: Scientific Advisory Board member (compensation waived). MEG – Consulting Fees: SeaGen (Tucatinib). MAG – Researcher: Fate Therapeutics, HCW Biologics; Consultant Advisor Speaker: Merck; NPI: 1265466809. AAJ – Consulting Fees: Nuprobe, Avenge Bio, BMS, Agenus, Instil Bio, GLG, Guidepoint, Macrogenics, Immune-Onc, Alkermes, EMD-Serono, Neo TILs, Genentech-Roche; Contracted Research: Iovance, AstraZeneca, BMS, Merck, Eli Lilly, Xencor, Immatics, Pfizer; Ownership Interest less than 5%: Avenge Bio. JBL – Contracted Research: Merck, Sanofi, AstraZeneca, Laekna, Sumitomo Dainippon Pharma Oncology, Harpoon Therapeutics, Precigen, Forty Seven. HM – Contracted Research: Puma Biotechnology. KO – Salary: The University of Chicago; IP Rights: PCT/US2014025673 “compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen, PCT/US2014025456“ enhancement of vaccines; Consulting Fees: GOG Foundation/Celsion, GSK, Dailchi-Sanyo; Contracted Research: Astra Zeneca research funding (grant), Tessaro Pharma research funding (grant). EZ – NPI: 1598921181. SAD, KCK, AM, VSJ – Nothing to disclose. SITC Staff – EG, AK, NL, SMW – Nothing to disclose.
(© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
التعليقات: Erratum in: J Immunother Cancer. 2023 Jun;11(6):1. (PMID: 37369392)
References: Front Oncol. 2020 Aug 05;10:1353. (PMID: 32850433)
Int J Gynecol Cancer. 2018 May;28(4):764-772. (PMID: 29538258)
Nature. 2013 Jul 11;499(7457):214-218. (PMID: 23770567)
Am J Transplant. 2019 May;19(5):1266-1277. (PMID: 30725527)
J Clin Oncol. 2018 Jul 1;36(19):1905-1912. (PMID: 29746230)
Mod Pathol. 2020 Jan;33(1):138-152. (PMID: 31383965)
J Clin Oncol. 2012 Jul 20;30(21):2654-63. (PMID: 22711857)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Ann Oncol. 2019 Jul 1;30(7):1080-1087. (PMID: 31046082)
J Clin Oncol. 2022 Mar 1;40(7):762-771. (PMID: 34932394)
Front Oncol. 2019 May 07;9:359. (PMID: 31134155)
Genet Med. 2019 Oct;21(10):2167-2180. (PMID: 31086306)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32209603)
Oncotarget. 2016 Mar 22;7(12):13587-98. (PMID: 26871470)
J Biol Chem. 2015 Nov 27;290(48):28675-82. (PMID: 26429911)
Gynecol Oncol. 2020 Aug;158(2):303-308. (PMID: 32507515)
Cancer. 2017 Mar 1;123(5):802-813. (PMID: 28061006)
Mod Pathol. 2017 Apr;30(4):577-586. (PMID: 28059093)
Cancer Res. 2014 Dec 1;74(23):6833-44. (PMID: 25273091)
J Cancer Res Ther. 2018 Dec;14(Supplement):S1063-S1069. (PMID: 30539847)
Future Oncol. 2014 Dec;10(16):2561-8. (PMID: 25531045)
Vaccines (Basel). 2021 Jan 25;9(2):. (PMID: 33503866)
Nat Rev Endocrinol. 2017 Apr;13(4):195-207. (PMID: 28106152)
Obstet Gynecol. 2015 Nov;126(5):1029-1039. (PMID: 26444112)
Front Oncol. 2021 Mar 19;11:538174. (PMID: 33816215)
Mod Pathol. 2015 Dec;28(12):1594-602. (PMID: 26403783)
J Natl Cancer Inst. 2022 Jun 13;114(6):808-818. (PMID: 34508604)
J Clin Oncol. 2018 Mar 20;36(9):850-858. (PMID: 29341833)
Arch Pathol Lab Med. 2022 Oct 1;146(10):1194-1210. (PMID: 35920830)
J Am Soc Cytopathol. 2020 Nov - Dec;9(6):485-493. (PMID: 32336671)
Gynecol Oncol Rep. 2017 Jun 27;21:78-80. (PMID: 28736741)
Oncol Lett. 2018 May;15(5):6457-6468. (PMID: 29616115)
Front Oncol. 2018 Dec 12;8:621. (PMID: 30631754)
Front Cell Dev Biol. 2020 Jul 21;8:672. (PMID: 32793604)
Lancet Oncol. 2019 Sep;20(9):1239-1251. (PMID: 31345627)
N Engl J Med. 2003 Jan 16;348(3):203-13. (PMID: 12529460)
Lancet. 2007 Jul 7;370(9581):59-67. (PMID: 17617273)
Lancet Oncol. 2020 Dec;21(12):1653-1660. (PMID: 33271094)
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. (PMID: 33580222)
Vaccines (Basel). 2020 Nov 05;8(4):. (PMID: 33167428)
J Clin Med. 2018 Dec 15;7(12):. (PMID: 30558290)
Int J Gynecol Cancer. 2021 Jun;31(6):801-806. (PMID: 33858954)
Onco Targets Ther. 2019 Sep 30;12:8015-8022. (PMID: 31686857)
Transl Gastroenterol Hepatol. 2020 Oct 05;5:54. (PMID: 33073049)
CA Cancer J Clin. 2021 Jul;71(4):287-298. (PMID: 33784415)
Lancet. 2016 Mar 12;387(10023):1094-1108. (PMID: 26354523)
Lancet Oncol. 2018 Mar;19(3):416-426. (PMID: 29370992)
N Engl J Med. 2009 Nov 5;361(19):1838-47. (PMID: 19890126)
Ann Oncol. 2007 May;18(5):945-9. (PMID: 17298959)
Gynecol Oncol. 2022 Aug;166(2):211-218. (PMID: 35361487)
Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526)
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1174-1183. (PMID: 31590148)
Clin Obstet Gynecol. 2020 Mar;63(1):48-63. (PMID: 31833846)
Anticancer Res. 2009 Aug;29(8):2875-84. (PMID: 19661290)
JAMA Oncol. 2019 Jul 01;5(7):1049-1054. (PMID: 30730549)
J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34716208)
Gynecol Oncol. 2018 May;149(2):410-419. (PMID: 29409684)
Gynecol Oncol. 2003 Mar;88(3):277-81. (PMID: 12648575)
JAMA Oncol. 2019 Oct 1;5(10):1504-1506. (PMID: 31415061)
Cancers (Basel). 2020 Jun 09;12(6):. (PMID: 32526888)
Ann Oncol. 2021 May;32(5):661-672. (PMID: 33736924)
J Immunother. 2019 Jul/Aug;42(6):228-235. (PMID: 30985445)
Gynecol Oncol. 2013 Aug;130(2):264-8. (PMID: 23623831)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
JCO Precis Oncol. 2017;2017:. (PMID: 29850653)
Oncotarget. 2017 Oct 6;8(54):92890-92903. (PMID: 29190964)
Expert Rev Anticancer Ther. 2018 Dec;18(12):1231-1239. (PMID: 30253680)
J Pers Med. 2021 May 12;11(5):. (PMID: 34065883)
Gynecol Oncol. 2003 Jun;89(3):434-9. (PMID: 12798708)
Am J Surg Pathol. 2019 Jun;43(6):792-801. (PMID: 31009388)
Support Care Cancer. 2020 Apr;28(4):1563-1578. (PMID: 31834518)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32238470)
J Clin Oncol. 2019 Aug 1;37(22):1927-1934. (PMID: 31206316)
World J Gastrointest Surg. 2012 Apr 27;4(4):87-95. (PMID: 22590662)
Cancer. 2019 Sep 15;125(18):3234-3241. (PMID: 31154669)
J Immunother Cancer. 2022 Jan;10(1):. (PMID: 35064011)
Eur J Cancer. 2018 Mar;91:21-29. (PMID: 29331748)
NPJ Precis Oncol. 2021 Dec 17;5(1):101. (PMID: 34921236)
Int J Gynecol Pathol. 2019 Sep;38(5):404-413. (PMID: 30134343)
J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33653801)
Eur J Cancer. 2019 Nov;121:192-201. (PMID: 31590080)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34266883)
Gynecol Oncol. 2012 Feb;124(2):192-8. (PMID: 22040834)
Transl Lung Cancer Res. 2018 Dec;7(6):661-667. (PMID: 30505710)
Eur J Cancer. 2005 Mar;41(5):673-5. (PMID: 15763641)
Clin Cancer Res. 2019 Dec 1;25(23):7024-7034. (PMID: 31506389)
Cancer. 2017 Apr 1;123(7):1202-1211. (PMID: 28117886)
N Engl J Med. 2021 Nov 11;385(20):1856-1867. (PMID: 34534429)
Mol Ther Oncolytics. 2021 Jul 21;22:410-430. (PMID: 34553029)
Front Pharmacol. 2017 Jan 06;7:519. (PMID: 28111549)
J Clin Oncol. 2017 Nov 1;35(31):3618-3632. (PMID: 28892432)
J Clin Pathol. 2020 Oct;73(10):656-664. (PMID: 32591352)
Ann Oncol. 2022 Apr;33(4):360-361. (PMID: 35033637)
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:79-85. (PMID: 30306586)
JAMA Netw Open. 2021 Mar 1;4(3):e211136. (PMID: 33760090)
Clin Cancer Res. 2008 Nov 1;14(21):6847-54. (PMID: 18980979)
Oncologist. 2019 Jun;24(6):e327-e337. (PMID: 30796151)
Br J Cancer. 1999 Aug;80(12):2008-18. (PMID: 10471054)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33199512)
Obstet Gynecol. 2015 Apr;125(4):833-842. (PMID: 25751200)
J Clin Oncol. 2018 Oct 1;36(28):2872-2878. (PMID: 30125216)
Clin Kidney J. 2021 May 08;14(9):2012-2022. (PMID: 34476087)
Target Oncol. 2021 Sep;16(5):553-568. (PMID: 34224061)
Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421)
J Immunother Cancer. 2021 Aug;9(8):. (PMID: 34389617)
Nat Genet. 2016 Aug;48(8):848-55. (PMID: 27348297)
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):111-9. (PMID: 12657109)
Oncologist. 2013;18(4):381-90. (PMID: 23442307)
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36. (PMID: 30306584)
J Clin Oncol. 2020 Sep 10;38(26):2981-2992. (PMID: 32167863)
N Engl J Med. 2020 Oct 1;383(14):1340-1348. (PMID: 32997908)
Ann Oncol. 2017 Feb 1;28(2):368-376. (PMID: 27687304)
Obstet Gynecol. 2014 Apr;123(4):817-21. (PMID: 24785610)
Gynecol Oncol. 2021 Jun;161(3):645-652. (PMID: 33795130)
Cancer. 2017 Apr 15;123(8):1333-1344. (PMID: 28026870)
Thyroid. 2014 Dec;24(12):1670-751. (PMID: 25266247)
Eur J Cancer. 2021 Jan;142:63-82. (PMID: 33221598)
Can Oncol Nurs J. 2019 Apr 1;29(2):87-91. (PMID: 31148748)
JCI Insight. 2019 Mar 21;4(6):. (PMID: 30895946)
J Immunother Cancer. 2021 Apr;9(4):. (PMID: 33931473)
Int J Gynecol Cancer. 2017 Mar;27(3):554-561. (PMID: 28060141)
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880. (PMID: 29330207)
N Engl J Med. 2022 Feb 3;386(5):437-448. (PMID: 35045221)
J Immunother Cancer. 2022 Feb;10(2):. (PMID: 35110358)
Cancer. 2017 Sep 1;123(17):3285-3290. (PMID: 28440953)
Ann Oncol. 2017 Jan 1;28(1):96-102. (PMID: 27742654)
J Clin Oncol. 2020 Jun 1;38(16):1814-1823. (PMID: 32275468)
PLoS One. 2018 Sep 26;13(9):e0204162. (PMID: 30256833)
Gynecol Oncol Rep. 2016 Apr 14;16:42-6. (PMID: 27331137)
J Womens Health (Larchmt). 2015 Feb;24(2):114-8. (PMID: 25525682)
Sci Rep. 2021 Oct 8;11(1):20003. (PMID: 34625576)
J Clin Oncol. 2014 May 20;32(15):1605-19. (PMID: 24733793)
Front Oncol. 2021 Mar 19;11:640018. (PMID: 33816285)
J Clin Med. 2020 Jun 29;9(7):. (PMID: 32610470)
J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550)
Diagn Pathol. 2017 Jun 17;12(1):45. (PMID: 28623908)
JAMA Oncol. 2015 Dec;1(9):1319-23. (PMID: 26181000)
Gynecol Oncol. 1991 Sep;42(3):197-201. (PMID: 1955180)
Gynecol Oncol. 2013 Apr;129(1):258-64. (PMID: 23266352)
AIDS Patient Care STDS. 2010 Aug;24(8):501-13. (PMID: 20666586)
J Sex Med. 2013 Feb;10 Suppl 1:21-34. (PMID: 23387909)
J Clin Oncol. 2017 Dec 1;35(34):3807-3814. (PMID: 28841387)
J Gen Intern Med. 2015 Dec;30(12):1857-64. (PMID: 26160483)
Oncol Lett. 2016 Aug;12(2):944-950. (PMID: 27446374)
Cancers (Basel). 2021 Jan 19;13(2):. (PMID: 33478080)
J Pain Symptom Manage. 2019 Jul;58(1):137-156.e1. (PMID: 30905677)
Front Oncol. 2020 Sep 23;10:1671. (PMID: 33072551)
Cancer Res. 2007 Jan 1;67(1):354-61. (PMID: 17210718)
Int J Womens Health. 2019 Apr 30;11:287-299. (PMID: 31118829)
JCO Precis Oncol. 2022 Feb;6:e2100267. (PMID: 35108036)
J Immunother Cancer. 2019 Apr 16;7(1):106. (PMID: 30992053)
Int J Gynecol Cancer. 2022 Aug 16;:. (PMID: 35973737)
Am J Clin Dermatol. 2020 Apr;21(2):285-295. (PMID: 31784896)
ESMO Open. 2021 Oct;6(5):100262. (PMID: 34487972)
N Engl J Med. 2022 Feb 10;386(6):544-555. (PMID: 35139273)
J Natl Cancer Inst. 2013 Jun 5;105(11):823-32. (PMID: 23539755)
Cancers (Basel). 2020 Feb 27;12(3):. (PMID: 32120803)
Front Mol Biosci. 2020 Jun 26;7:122. (PMID: 32671096)
Science. 2016 Mar 25;351(6280):1463-9. (PMID: 26940869)
Cancer. 2005 Aug 1;104(3):618-28. (PMID: 15973737)
Br J Cancer. 2018 Jan;118(1):9-16. (PMID: 29319049)
J Obstet Gynaecol. 2020 Jul;40(5):602-608. (PMID: 31500479)
JAMA Oncol. 2019 Jan 1;5(1):67-73. (PMID: 30267032)
Cell. 2020 Dec 10;183(6):1634-1649.e17. (PMID: 33259803)
Gynecol Oncol. 2015 Nov;139(2):377-84. (PMID: 26335596)
Br J Cancer. 2007 Oct 22;97(8):1135-8. (PMID: 17940503)
Mod Pathol. 2017 Apr;30(4):549-562. (PMID: 28059099)
J Pathol. 2000 Nov;192(3):328-35. (PMID: 11054716)
Clin Cancer Res. 2009 Dec 1;15(23):7412-20. (PMID: 19934295)
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. (PMID: 33891472)
J Hematol Oncol. 2018 Aug 16;11(1):104. (PMID: 30115069)
Medicine (Baltimore). 2020 Jan;99(5):e19013. (PMID: 32000444)
Gynecol Oncol Rep. 2017 Jul 25;21:98-100. (PMID: 28795132)
Melanoma Res. 2022 Apr 1;32(2):71-78. (PMID: 35254329)
Mol Med Rep. 2017 Mar;15(3):1063-1070. (PMID: 28075442)
Acta Obstet Gynecol Scand. 2012 Aug;91(8):976-82. (PMID: 22548255)
EClinicalMedicine. 2021 Sep 16;41:101134. (PMID: 34585125)
J Clin Oncol. 2019 Jun 10;37(17):1470-1478. (PMID: 30943124)
J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33033183)
JAMA Oncol. 2019 Aug 01;5(8):1141-1149. (PMID: 31194228)
Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869)
Mod Pathol. 2019 Mar;32(3):396-404. (PMID: 30291344)
Eur J Cancer. 2021 Sep;155:291-293. (PMID: 34400057)
Psychooncology. 2013 Apr;22(4):745-55. (PMID: 22411485)
J Immunother Cancer. 2022 Mar;10(3):. (PMID: 35264438)
Clin Cancer Res. 2015 Jul 15;21(14):3347-3355. (PMID: 25878334)
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. (PMID: 30787022)
J Cancer Res Clin Oncol. 2019 Jun;145(6):1651-1660. (PMID: 30972492)
Int J Gynecol Cancer. 2011 May;21(4):661-7. (PMID: 21412164)
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. (PMID: 17360651)
J Thorac Oncol. 2018 Nov;13(11):1771-1775. (PMID: 29935305)
Cancer Control. 2009 Jan;16(1):14-22. (PMID: 19078925)
Int J Gynecol Cancer. 2020 Dec;30(12):1990-1996. (PMID: 33109526)
J Transl Med. 2013 Apr 04;11:88. (PMID: 23557172)
Front Oncol. 2016 Feb 22;6:36. (PMID: 26942126)
J Immunother Cancer. 2019 Dec 17;7(1):353. (PMID: 31847881)
Lancet Oncol. 2021 Nov;22(11):1609-1617. (PMID: 34624252)
J Clin Oncol. 2017 Aug 1;35(22):2535-2541. (PMID: 28489510)
Mod Pathol. 2022 Dec;35(12):1775-1783. (PMID: 36104536)
Int J Gynaecol Obstet. 2009 May;105(2):103-4. (PMID: 19367689)
Lancet. 2017 Nov 25;390(10110):2343-2345. (PMID: 29185430)
J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34226279)
Obstet Gynecol. 2010 Nov;116(5):1141-9. (PMID: 20966700)
JCO Precis Oncol. 2021 Jun 08;5:953-973. (PMID: 34136742)
Int J Cancer. 2013 Dec 15;133(12):2884-94. (PMID: 23740735)
J Clin Oncol. 2020 Oct 10;38(29):3388-3397. (PMID: 32749941)
JAMA Netw Open. 2019 Jun 5;2(6):e195718. (PMID: 31199446)
JAMA. 2004 Jun 9;291(22):2720-6. (PMID: 15187053)
Int J Gynecol Pathol. 2014 Sep;33(5):483-91. (PMID: 25083964)
Cancer Res. 2019 Mar 15;79(6):1214-1225. (PMID: 30541742)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
Int J Gynecol Cancer. 2018 Jan;28(1):134-138. (PMID: 29040191)
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:45-60. (PMID: 34669196)
Immunotargets Ther. 2020 Oct 07;9:167-200. (PMID: 33117742)
Nat Immunol. 2002 Feb;3(2):196-200. (PMID: 11812998)
Cancer Discov. 2022 Mar 1;12(3):654-669. (PMID: 34876409)
Cancer Discov. 2021 Aug;11(8):1896-1912. (PMID: 33990345)
Am J Surg Pathol. 2016 Aug;40(8):1133-42. (PMID: 27158757)
Lancet Oncol. 2012 Feb;13(2):154-62. (PMID: 22192729)
Ann Thorac Surg. 2008 Mar;85(3):1049-55. (PMID: 18291195)
N Engl J Med. 2023 Jun 8;388(23):2159-2170. (PMID: 36972022)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34697217)
N Engl J Med. 2023 Jun 8;388(23):2145-2158. (PMID: 36972026)
Cancers (Basel). 2020 Nov 10;12(11):. (PMID: 33182707)
J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33067316)
PLoS One. 2020 Jan 24;15(1):e0227344. (PMID: 31978145)
Front Oncol. 2021 Jun 04;11:678758. (PMID: 34150643)
Curr Oncol. 2021 Aug 25;28(5):3259-3267. (PMID: 34449588)
Gynecol Oncol. 2011 May 1;121(2):353-7. (PMID: 21324516)
Radiology. 2020 Oct;297(1):87-96. (PMID: 32749204)
Clin Cancer Res. 2013 Jul 15;19(14):3936-43. (PMID: 23743568)
Clin Cancer Res. 2016 May 15;22(10):2342-50. (PMID: 26813357)
Lancet. 2019 Aug 10;394(10197):497-509. (PMID: 31255301)
Cancer. 2002 Jan 1;94(1):131-40. (PMID: 11815969)
Front Oncol. 2013 Sep 25;3:256. (PMID: 24093089)
BMC Med Genomics. 2020 Jul 11;13(1):101. (PMID: 32652986)
Anticancer Res. 2018 Dec;38(12):6891-6895. (PMID: 30504406)
Mod Pathol. 2022 Feb;35(2):142-151. (PMID: 34493822)
Eur J Cancer. 2021 May;149:153-164. (PMID: 33865201)
Lancet Oncol. 2021 Jul;22(7):1034-1046. (PMID: 34143970)
Cancers (Basel). 2020 Dec 11;12(12):. (PMID: 33322519)
J Clin Oncol. 2020 Sep 20;38(27):3129-3137. (PMID: 32716740)
Exp Hematol Oncol. 2018 Nov 16;7:28. (PMID: 30473928)
Am J Surg Pathol. 2020 Feb;44(2):174-181. (PMID: 31651527)
Cancer Res. 2019 Jan 15;79(2):311-319. (PMID: 30482774)
Clin Infect Dis. 2020 Jan 2;70(2):193-199. (PMID: 30874791)
Ann Oncol. 2020 Jun;31(6):724-744. (PMID: 32194150)
Mod Pathol. 2016 Jul;29(7):753-63. (PMID: 27056074)
J Pathol. 1999 Sep;189(1):12-9. (PMID: 10451482)
Nature. 2013 May 2;497(7447):67-73. (PMID: 23636398)
Int J Gynecol Cancer. 2018 Jan;28(1):59-68. (PMID: 29053481)
Eur J Cancer. 2019 Nov;121:94-97. (PMID: 31569067)
N Engl J Med. 2002 May 2;346(18):1400-2. (PMID: 11986416)
Int J Gynecol Cancer. 2004 Jan-Feb;14(1):110-7. (PMID: 14764038)
Cell Death Dis. 2020 Sep 23;11(9):790. (PMID: 32989221)
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52):. (PMID: 29140490)
J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34172516)
Clin Cancer Res. 2020 May 15;26(10):2290-2296. (PMID: 31969335)
Ann Oncol. 2019 Apr 1;30(4):582-588. (PMID: 30715153)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
BMC Cancer. 2016 Nov 8;16(1):861. (PMID: 27821099)
Mod Pathol. 2019 May;32(5):650-658. (PMID: 30443012)
Br J Cancer. 2015 Jul 14;113(2):299-310. (PMID: 26172027)
Nature. 2012 Jan 18;481(7381):306-13. (PMID: 22258609)
J Clin Oncol. 2019 Nov 1;37(31):2825-2834. (PMID: 31487218)
JAMA Oncol. 2021 Jan 01;7(1):78-85. (PMID: 33211063)
Vaccines (Basel). 2020 Jan 25;8(1):. (PMID: 31991753)
JAMA Oncol. 2020 Nov 01;6(11):1766-1772. (PMID: 33001143)
J Bone Oncol. 2020 Jan 08;21:100275. (PMID: 31956475)
فهرسة مساهمة: Keywords: Clinical Trials as Topic; Genital Neoplasms, Female; Guidelines as Topic
تواريخ الأحداث: Date Created: 20230609 Date Completed: 20230613 Latest Revision: 20240105
رمز التحديث: 20240105
مُعرف محوري في PubMed: PMC10277149
DOI: 10.1136/jitc-2022-006624
PMID: 37295818
قاعدة البيانات: MEDLINE
الوصف
تدمد:2051-1426
DOI:10.1136/jitc-2022-006624